Clinical trials: Food Allergy Peanut
Food Allergy
A Study to Assess Primarily the Tolerability and Safety of SAR439794 After Repeated Sublingual Daily Administration in Peanut Allergic Adult and Adolescent Patients
Primary Objective: To assess tolerability and safety of SAR439794 [peanut extract (PE) sublingual immunotherapy (SLIT) adjuvanted with Glucopyranosyl Lipid A (GLA)] after repeated sublingual (SL) daily administration in peanut…
- Trial name
- NCT03463135
- Testing
- Glucopyranosyl Lipid A (GLA), Sublingual Immuno Therapy (SLIT) Peanut Extract (PE)
- Where
- 16 sites in United States
- Volunteers
- 27 people
- Sponsor
- Sanofi
Food Allergy in Children, Food Allergy Peanut
Pathway to Peanut Tolerance
While rigorous clinical trials have established peanut OIT as a promising therapy capable of inducing desensitization and even remission, its transition to routine clinical practice requires robust real-world evidence.
- Trial name
- NCT07592780
- Testing
- Peanut Oral Immunotherapy (OIT)
- Where
- Hong Kong
- Volunteers
- 125 people
- Sponsor
- Chinese University of Hong Kong
Peanut Allergy
Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy
This clinical research study investigates the safety, tolerability and efficacy of a peanut SLIT-tablet in adults, adolescents, and children with peanut allergy.
- Trial name
- NCT05440643
- Testing
- Peanut SLIT-tablet
- Where
- 42 sites in United States, Canada
- Volunteers
- 209 people
- Sponsor
- ALK-Abelló A/S
Peanut Allergy
Reduction of Peanut Reactivity and Immune Modulation With Anti-IgE Therapy
This pilot study is will examine the pathways involved in allergic response, primarily in food allergy; specifically peanut allergy.
- Trial name
- NCT02194530
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Food Hypersensitivity, Peanut Hypersensitivity
Mechanisms Underlying Peanut Allergic Reactions in TRACE Peanut Study Participants: Extension Study
Food allergy affects up to 10% of the population. The mainstay of management involves dietary avoidance and provision of rescue medication in the event of an accidental reaction.
- Trial name
- TRACEextension (NCT02665793)
- Testing
- DBPCFC to peanut cookie, Single-dose DBPCFC to peanut flour, Single-dose DBPCFC to peanut butter
- Volunteers
- 17 people
- Sponsor
- Imperial College London
Peanut Allergy
Viaskin® Peanut (DBV712) Expanded Access Protocol
This is an open label expanded access program for male and female patients ≥ 4 years old.
- Trial name
- NCT04371627
- Testing
- Viaskin Peanut
- Sponsor
- DBV Technologies
Food Allergy
The Effect of Per Oral Immunotherapy in Severe Milk, Peanut and Egg Allergy in Adults
The aim is to analyse the results of per oral immunotherapy treatment in severe milk, peanut or egg allergy in adults. This is the second part of the oral immunotherapy study in adults at Skin and Allergy Hospital.
- Trial name
- NCT03361072
- Testing
- Oral immunotherapy
- Where
- Finland
- Volunteers
- 30 people
- Sponsor
- Helsinki University Central Hospital
Food Hypersensitivity
A Study of Sublingual Immunotherapy in Peanut-allergic Children
The specific aim of this study is to determine if peanut allergen-specific SLIT will cause clinical desensitization and tolerance to develop in peanut-allergic young children.
- Trial name
- SLB (NCT00597727)
- Testing
- Peanut SLIT
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of North Carolina, Chapel Hill
Peanut Allergy
Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents
To compare the HRQOL of AR101 characterized oral desensitization immunotherapy (CODIT™) in combination with standard of care (peanut avoidance, education) versus standard of care alone in peanut-allergic subjects aged 4 to 17…
- Trial name
- NCT03703791
- Testing
- AR101
- Where
- 11 sites in Spain
- Volunteers
- 1 people
- Sponsor
- Aimmune Therapeutics, Inc.
Peanut Allergy
HAL-MPE1 First-in-human
Currently, there is no effective causal treatment for peanut allergy. A chemically modified, aluminium hydroxide adsorbed peanut extract (HAL-MPE1) for subcutaneous administration has been developed.
- Trial name
- HAL-MPE1/0043 (NCT02163018)
- Testing
- HAL-MPE1
- Where
- Denmark
- Volunteers
- 17 people
- Sponsor
- HAL Allergy
Peanut Allergy
Oral Immunotherapy for Peanut Allergic Patients
Multicenter, double-blind, randomized, placebo-controlled phase I/II study to determine the safety, tolerability, potential efficacy and dose finding of INP20, an oral immunotherapy in peanut-allergic patients.
- Trial name
- NCT04163562
- Testing
- INP20
- Where
- 2 sites in Spain
- Volunteers
- 50 people
- Sponsor
- InnoUp Farma S.L.
Peanut Hypersensitivity
The Effect of Extrinsic Factors on Food Allergy
Food allergy is a common problem, affecting 5-8% of the population. Peanut allergy causes reduced quality of life due to the perceived high risk of severe reactions.
- Trial name
- Ex-Factor (NCT01429896)
- Testing
- Food challenge
- Where
- 2 sites in United Kingdom
- Volunteers
- 100 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Peanut Allergy
HAL-MPE1 Safety and Tolerability Study
The aim of this study is to confirm safety and tolerability of incremental doses of HAL-MPE1 subcutaneous immunotherapy (SCIT) in peanut allergic adults, and subsequently assess the safety and tolerability in adolescents and…
- Trial name
- NCT02991885
- Testing
- HAL-MPE1
- Where
- 7 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- HAL Allergy
Allergy, Peanut
Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy
This was a 52-week, Phase 3 multi-center, randomized, double-blind and placebo-controlled study to assess the safety and clinical efficacy of two dosing regimens of ligelizumab (240 mg and 120 mg) SC q4w (subcutaneous injection…
- Trial name
- NCT04984876
- Testing
- ligelizumab
- Where
- 55 sites in United States, Australia and 8 more
- Volunteers
- 211 people
- Sponsor
- Novartis Pharmaceuticals
Peanut Allergy, Peanut Hypersensitivity
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
The overall aims of this study are to demonstrate that treatment with PVX108 immunotherapy has an acceptable safety profile and is effective for reducing clinical reactivity to peanut protein in children and adolescents with…
- Conditions
- Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis, Immune System Diseases
- Trial name
- NCT05621317
- Testing
- PVX-108
- Where
- 14 sites in United States, Australia
- Volunteers
- 90 people
- Sponsor
- Aravax Pty Ltd
Food Allergy, Peanut Allergy
Pilot Study on Immunotherapy for the Treatment of Persistant Peanut Allergy
The purpose of this trial is to assess the safety and efficacy of peanut immunotherapy in children and adults with peanut allergy. Participants will receive immunotherapy with peanut every 2 weeks for a period of 3 months.
- Trial name
- NCT04974970
- Testing
- Peanut Immunotherapy
- Where
- Switzerland
- Volunteers
- 12 people
- Sponsor
- University Hospital, Geneva
Allergy, Peanut Allergy
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
The primary objective of this study is to assess the 6-month safety of DBV712 250 micrograms (mcg) in subjects 1 through 3 years of age with peanut allergy.
- Trial name
- NCT07003919
- Testing
- DBV712 250 mcg
- Where
- 91 sites in United States, Australia and 6 more
- Volunteers
- 480 people
- Sponsor
- DBV Technologies
Peanut and Tree Nut Allergy
Accidental Reactions in Peanut/Tree Nut Allergic Children
Food allergy is an immune reaction, triggered by food protein allergens, of varying severity, from mild local reaction to life threatening anaphylaxis and fatalities.
- Trial name
- ALLERGY (NCT05671471)
- Where
- France
- Volunteers
- 147 people
- Sponsor
- University Hospital, Lille
Peanut Allergy
The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery
Determine whether peanut oral immunotherapy (OIT) induces clinical tolerance as assessed after the initial 3 month avoidance period Secondary Objectives: Identify the basic immune mechanisms which can explain the differences in…
- Trial name
- POISED (NCT02103270)
- Testing
- Peanut Protein 4,000mg, Oat Flour, Peanut Protein 300 mg
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Stanford University
Peanut Allergy
ARTEMIS Peanut Allergy In Children
The purpose of this study is to demonstrate the efficacy and safety of AR101 through oral immunotherapy (OIT) in peanut-allergic children.
- Trial name
- ARTEMIS (NCT03201003)
- Testing
- AR101 powder provided in capsules & sachets
- Where
- 18 sites in France, Germany and 5 more
- Volunteers
- 175 people
- Sponsor
- Aimmune Therapeutics, Inc.